Role of the pharmacokinetic-pharmacodynamic relationship in drug development;Place de la relation pharmacocinétique-pharmacodynamique dans le développement des médicaments

Therapie

Volumn 57, Issue 4, 2002, Pages 347-357

  Bellissant, E ^a   Courcier Duplantier, S ^b   Blin, O ^c  

^a Laboratoire de Pharmacologie   (France)

^b Produits Roche   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Drug development; Pharmacodynamics; Pharmacokinetics; Phase I; Phase II; Phase III; PK PD modeling

Indexed keywords

NEW DRUG;

AGE; AGED; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG RESEARCH; HUMAN; MEDICAL LITERATURE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

CLINICAL TRIALS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; RESEARCH DESIGN;

EID: 0036660958     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Chaikin P, Rhodes GR, Bruno R, et al. Pharmacokinetics/Pharmacodynamics in Drug Development: An Industrial Perspective. J Clin Pharmacol 2000; 40: 1428-1438
2. Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development. J Clin Pharmacol 2000; 40: 1399-1418
3. Peck CC, Barr WH, Benet LZ, et al. Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Clin Pharmacol Ther 1992; 51: 465-473
4. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-453
5. Bellissant E, Sébille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998; 35: 151-166
6. Danhof M. Applications of Pharmacokinetic/Pharmacodynamic Research in Rational Drug Development. Meth Find Exp Clin Pharmacol 1996; 18(Suppl C): 53-54
7. Jochemsen R, Laveille C, Breimer DD. Application of Pharmacokinetic/Pharmacodynamic Modelling and Population Approaches to Drug Development. Int J Pharm Med 1999; 13: 243-251
8. Dupuis A, Couet W, Paquereau J, et al. Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Imipenem in Healthy Rats. Antimicrob Agents Chemother 2001; 45: 1682-1687
9. Van Peer A, Snoeck E, Huang ML, Heykants J. Pharmacokinetic-Pharmacodynamic Relationships in Phase I/Phase II of Drug Development. Eur J Drug Metab Pharmacokinet 1993; 18: 49-59
10. Kroboth PD, Schmith VD, Smith RB. Pharmacodynamic Modelling. Application to New Drug Development. Clin Pharmacokinet 1991; 20: 91-98
11. Wade JR, Sambol NC. Felodipine Population Dose-Response and Concentration-Response Relationships in Patients with Essential Hypertension. Clin Pharmacol Ther 1995; 57: 569-581
12. Tod M, Lokiec F, Bidault R, et al. Pharmacokinetic of Oral Acyclovir in Neonates and in Infants: a Population Analysis. Antimicrob Agents Chemother 2001; 45: 150-157
13. Marshall JD, Kearns GL. Developmental Pharmacodynamics of Cyclosporine. Clin Pharmacol Ther 1999; 66: 66-75
14. Sheiner LB, Steimer JL. Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95
15. Reigner BG, Williams PEO, Patel IH, et al. An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development. Experience within Hoffmann La Roche. Clin Pharmacokinet 1997; 33: 142-152